NCT02919475View on ClinicalTrials.gov

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

260

Participants

Timeline

Start Date

September 14, 2016

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions

Rheumatoid Arthritis

Interventions

DRUG

JTE-051

Active drug tablets containing JTE-051

DRUG

Placebo

Placebo tablets identical in appearance to the active drug tablets

Trial Locations (39)

Unknown

Tucson

Upland

Clearwater

Hendersonville

La Plata

San Fernando

Barrio Norte

San Miguel de Tucumán

Córdoba

San Juan

Lom

Plovdiv

Sevlievo

Sofia

Medellín

Bogotá

Santiago de Cali

Mexicali

Guadalajara

Mexico City

San Luis Potosí City

Mérida

Lima

Warsaw

Bialystok

Elblag

Bucharest

Iași

Târgu Mureş

Kazan'

Moscow

Saint Petersburg

Kharkiv

Kherson

Kyiv

Lviv

Sumy

Vinnytsia

Zaporizhzhia

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT02919475 - Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter